Provided by Tiger Trade Technology Pte. Ltd.

Elicio Therapeutics

3.04
-0.0350-1.14%
Pre-market: 3.100.0600+1.97%07:31 EDT
Volume:279.27K
Turnover:855.97K
Market Cap:79.90M
PE:-1.40
High:3.11
Open:3.11
Low:3.03
Close:3.08
52wk High:16.00
52wk Low:2.66
Shares:26.28M
Float Shares:19.19M
Volume Ratio:0.93
T/O Rate:1.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1721
EPS(LYR):-2.5842
ROE:-774.56%
ROA:-77.88%
PB:10.07
PE(LYR):-1.18

Loading ...

Company Profile

Company Name:
Elicio Therapeutics
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
33
Office Location:
451 D Street,5th Floor,Suite 501,Boston,Massachusetts,United States
Zip Code:
02210
Fax:
- -
Introduction:
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.

Directors

Name
Position
Robert Connelly
President,Chief Executive Officer and Director
Allen R. Nissenson
Independent Director
Carol Ashe
Independent Director
Julian Adams
Chair of Board and Independent Director
Karen Wilson
Independent Director
Robert R. Ruffolo, Jr.
Independent Director
Jay Venkatesan
Director
Yekaterina Chudnovsky
Director

Shareholders

Name
Position
Robert Connelly
President,Chief Executive Officer and Director
Christopher Haqq
Executive Vice President, Head of Research and Development and Chief Medical Officer
Peter DeMuth
Chief Scientific Officer
Preetam Shah
Chief Strategy and Financial Officer and Treasurer